Analysis Monte Rosa Therapeutics, Inc. (GLUE)
5/28/2024
Analysis of Monte Rosa Therapeutics, Inc. (GLUE)
Monte Rosa Therapeutics, Inc. is a biotechnology company focused on developing novel therapeutics to degrade disease-causing proteins. The company's approach involves targeting specific proteins for degradation, offering a unique and potentially powerful way to treat a variety of diseases.In terms of financial performance, Monte Rosa Therapeutics, Inc. is a relatively new company and may not have a long track record of financial data available for analysis. Investors interested in the company should consider factors such as its pipeline of drug candidates, partnerships with other biopharmaceutical companies, and the expertise of its management team.
Overall, Monte Rosa Therapeutics, Inc. appears to be an innovative company with a promising approach to drug development. However, as with any biotechnology company, there are inherent risks associated with investing in early-stage companies in this industry. Investors should conduct thorough research and consider consulting with a financial advisor before making any investment decisions.
Revenue estimate
Based on the analysts' estimates for the future quarterly and annual sales of the company, we can draw the following conclusions:1. For the current quarter ending on June 30, 2024, the average sales estimate is $83,776,900,000, with a sales growth of 2% compared to the same quarter last year. The number of analysts providing estimates is 24.
2. For the next quarter ending on September 30, 2024, the average sales estimate is $92,375,300,000, with a sales growth of 3% compared to the same quarter last year. The number of analysts providing estimates is 24.
3. For the current fiscal year ending on September 30, 2024, the average sales estimate is $386,681,000,000, with a sales growth of 1% compared to the previous fiscal year. The number of analysts providing estimates is 37.
4. For the next fiscal year ending on September 30, 2025, the average sales estimate is $411,555,000,000, with a sales growth of 6% compared to the current fiscal year. The number of analysts providing estimates is 37.
These estimates suggest a moderate growth trend in both quarterly and annual sales for the company, with slightly higher growth expected in the next fiscal year compared to the current one.
Growth estimates
Based on the consensus estimates provided:- The company is expected to experience a growth rate of 7.5% in the current year and 9.7% in the next year.
- For the current quarter, the growth rate is estimated to be 5.6%, while for the next quarter it is projected to be 4.8%.
- Over the next 5 years, the company is expected to have a compound annual growth rate (CAGR) of 11%.
- However, when looking at the past 5 years, the company has had a higher CAGR of approximately 20.1%.
Overall, the company is expected to maintain a solid growth trajectory, with a slightly higher growth rate projected for the next 5 years compared to the current and upcoming shorter periods.
Price target
Based on the analysts' forecast, the future price of the security is expected to range between $164 (low) and $250 (high), with a median estimate of $200 and an average estimate of $202.26. The current price of the security is $191.57.Earnings
The company's results for the most recent quarter ending on April 30, 2025, have not been provided yet. The previous results were reported on February 27, 2025, through the Transfer Agent. Before that, on January 31, 2025, the results were released after hours. The results for the quarter ending on October 31, 2024, were not provided at the time. However, on August 1, 2024, the company reported an earnings per share (EPS) estimate of 1.32.Main Statystic ðŸ§
The data provided includes financials, stock statistics, valuation metrics, stock price summary, and dividends and splits information for a specific company.In terms of financials, the company has a strong operating cash flow and levered free cash flow. The balance sheet shows a healthy current ratio, but a high total debt to equity ratio. The profit margin and operating margin are both positive, indicating profitability. The company's fiscal year ends in September 2023, and the most recent quarter reported is March 2024. The company has a good return on assets and return on equity.
Stock statistics show details such as short ratio, float shares, shares outstanding, and percentages held by insiders and institutions. Valuation metrics include PEG ratio, PE ratios, enterprise value, price to book, price to sales, and market capitalization. The stock price summary provides information on beta, moving averages, and the 52-week high and low.
Lastly, dividends and splits data include payout ratio, dividend dates, split dates, dividend rates, and dividend yields.
Income statement 💸
These are the revenues. Here are the conclusions:1. The company's sales revenue has been increasing steadily over the years, from $274.5 billion in 2020 to $383.3 billion in 2023.
2. Despite the increase in sales, the cost of goods sold has also been rising, indicating that the company is experiencing higher production or acquisition costs.
3. The gross profit margin has remained relatively stable over the years, indicating that the company has been able to maintain its profitability despite the increase in costs.
4. Operating income has also shown a consistent growth trend, reaching $114.3 billion in 2023 from $66.3 billion in 2020.
5. Net income has been increasing over the years, reflecting the company's ability to manage its expenses and generate profits.
6. Earnings per share (EPS) have shown a slight fluctuation but have generally been on an upward trajectory, indicating that the company's profitability is being distributed among shareholders.
7. The company has been able to effectively manage its taxes, with the income tax expense increasing in line with the growth in revenue.
8. Overall, the financial performance of the company, as indicated by its revenues, shows a positive growth trend over the years.
Balance Sheet
These are balance sheets. Here are the conclusions:1. The total assets have been increasing over the years, reaching $365,725,000,000 in 2018.
2. Current assets fluctuate, with the highest value in 2019 at $162,819,000,000.
3. Non-current assets have been increasing steadily, with the highest value in 2019 at $175,697,000,000.
4. Total liabilities have also been increasing, reaching $255,355,000,000 in 2018.
5. Shareholders' equity has been increasing over the years, with the highest value in 2018 at $107,147,000,000.
Cash Flow 💶
This is the cash flow statement. Here are some conclusions we can draw from the data:1. The company's free cash flow has been fluctuating over the years, with the highest value recorded in 2022 and the lowest in 2020.
2. Operating cash flow has generally been increasing year over year, indicating improved operational efficiency.
3. The company has been consistently paying interest and income taxes, with varying amounts each year.
4. Financing activities show a pattern of common stock repurchase and issuance, as well as long-term debt issuance and payments.
5. Investing activities include the sale and purchase of investments, capital expenditures, and other investing activities.
6. The end cash position has also been fluctuating, reaching its highest value in 2020 and its lowest in 2022.
These conclusions provide insights into the company's financial performance and management of cash flows over the years.
Earnings estimate
Based on analysts' estimates for future quarterly and annual earnings per share:1. For the current quarter ending on June 30, 2024, the average EPS estimate is $1.33, with a range from $1.27 to $1.36. This shows growth compared to the EPS of $1.26 from the same quarter a year ago.
2. For the next quarter ending on September 30, 2024, the average EPS estimate is $1.53, with a range from $1.44 to $1.63. This indicates a slight increase from the EPS of $1.46 from the same quarter a year ago.
3. For the current year ending on September 30, 2024, the average EPS estimate is $6.59, with a range from $6.43 to $6.92. This reflects growth compared to the EPS of $6.13 from the previous year.
4. For the next year ending on September 30, 2025, the average EPS estimate is $7.23, with a range from $6.40 to $7.90. This shows a potential increase from the EPS of $6.59 from the previous year.
Overall, the analysts' estimates suggest a positive outlook for the company's earnings per share, with expected growth in both the short term and the long term.
MACD of GLUE
This is not investment advice. Remember to verify the information provided here.
Get access to the full analysis
- Over 35 000 indexes
- CFD, Forex, Crypto and Stocks Exchange
- Over 150 Indicators
- Pattern and candle analysis
- Support and resistance levels
- Fundamental, technical and sentimental analysis
- Power from AI
